Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: Ann Surg Oncol. 2019 Jul 24;26(10):3166–3177. doi: 10.1245/s10434-019-07564-9

Fig. 2 — Unadjusted overall survival, women with cT1-4c, cN1-3, HR+ invasive lobular carcinoma who received endocrine therapy or chemotherapy, National Cancer Data Base, 2004–2014 (N = 18,154). ACT adjuvant chemotherapy, AET adjuvant endocrine therapy, NACT neoadjuvant chemotherapy, NET neoadjuvant endocrine therapy

Fig. 2 — Unadjusted overall survival, women with cT1-4c, cN1-3, HR+ invasive lobular carcinoma who received endocrine therapy or chemotherapy, National Cancer Data Base, 2004–2014 (N = 18,154). ACT adjuvant chemotherapy, AET adjuvant endocrine therapy, NACT neoadjuvant chemotherapy, NET neoadjuvant endocrine therapy